patent.fyi
Applications  /  US 2026/0356848
United States Patent Application Publication

US 2026/0356848 A1

Published
Nov 12, 2026
Filed
Feb 11, 2026
Earliest date on the face
Aug 15, 2017
Classification
C07D 495/16
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Carbon at the A3 position

What ifWhat if A3 were an aromatic carbon bearing hydrogen?
Claim language“A3 is N”

The sp² carbon forms bonds to both neighboring ring atoms and contributes a p orbital to the aromatic π system. The C–H site preserves the ring atom count and removes the hydrogen-bond acceptor at A3.

1.2Nitrogen at the A4 position

What ifWhat if A4 were an aromatic NH group?
Claim language“A4 is O or S”

The NH nitrogen bonds to both neighboring ring atoms. Its lone pair contributes two electrons to the aromatic π system, and its N–H bond provides a hydrogen-bond donor.

1.6Ethynyl substitution at RA

What ifWhat if RA were a terminal ethynyl group?
Claim language“RA is hydrogen, CH3, halogen, CN, CH2F, CHF2, or CF3”

The scaffold bonds directly to the proximal sp carbon of —C≡CH. The triple bond places the terminal carbon along the attachment axis and gives the substituent a linear two-carbon geometry.

1.7Thioether at the X position

What ifWhat if X were a divalent sulfur atom in a thioether linkage?
Claim language“X is O, or N(Rx2)”

A neutral sulfur atom forms one single bond to each carbon flanking X and completes the macrocyclic path at that position. The two C–S bonds give this bridge a longer bond path than a C–O–C bridge.

1.10Thioether within the Y tether

What ifWhat if one internal CH2 group in Y were replaced by unoxidized divalent sulfur?
Claim language“O, N(Rya), C(Rya)(Ryb), C(O), NC(O)Rya, or S(O)2”

A four-position saturated tether takes the form —CH2—S—CH2—CH2—. Sulfur bonds to the two adjacent methylene groups, maintaining a continuous four-atom path between the tether endpoints.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Component substitution

Tetrahydrofuran replaces the cyclic acetal

A tetrahydrofuran-3-yl group replaces a 1,3-dioxolan-4-yl group at the same aryl attachment site through a direct carbon–carbon bond. Both substituents have five-membered rings, and the tetrahydrofuran ring contains one oxygen where the dioxolane ring contains two. A solution binding assay compares the resulting macrocycle with its dioxolane counterpart using the same concentration series.

An oxadiazole replaces the pendant aryl group

A 5-methyl-1,2,4-oxadiazol-3-yl group replaces an R11 phenyl group at the bond to W. The oxadiazole connects to W through carbon 3, with methyl at carbon 5 and a cyclic acetal elsewhere on the macrocycle. A matched-pair assay measures how the change in aromatic ring size and heteroatom content affects MCL-1 binding.

Parameter or scale variation

Six and seven carbon tethers

Two matched macrocycles use saturated Y tethers of six and seven methylene units. Both tethers connect the same attachment atoms, and the pair uses identical X and W groups and pendant substituents. A ring-closing reaction joins the corresponding linear precursors at the same bond to produce a pair whose macrocyclic paths differ by one carbon atom.

Combination with existing systems

Macrocycles in a calorimetry binding system

An isothermal titration calorimeter measures binding between a purified macrocycle and the isolated MCL-1 binding domain. The protein occupies the sample cell, and the injection syringe delivers successive aliquots of the macrocycle in matched buffer. A ligand-into-buffer run measures dilution heat, which is subtracted before fitting the integrated binding heats for affinity and stoichiometry.

Automated or data-driven variant

Software enumerates and checks macrocycle structures

A program stores the heterocyclic core, the X and Y fragments, and the pendant groups as molecular graphs with labeled attachment atoms. It joins fragments at matching labels, checks atom valences, and counts the atoms along the closed path that contains Y. It assigns each structure a canonical identifier that preserves stereochemistry and removes duplicate entries before export.

Specific version of a part

Oxygen at the A4 position

A2 is C–H, A3 and A6 are carbon, and A4 is oxygen. The A4 oxygen forms two bonds within the heterocyclic ring.

Sulfur at the A4 position

A2 is nitrogen, A3 and A6 are carbon, and A4 is sulfur. The A4 sulfur forms two bonds to adjacent ring atoms and carries no attached oxygen.

Cyclopropyl on the linker nitrogen

X is N(Rx2), and Rx2 is unsubstituted cyclopropyl. The nitrogen bonds directly to one cyclopropyl carbon and to the two atoms that flank X in the macrocycle.

Cis alkene within the tether

Y is —CH2—CH═CH—CH2— with Z geometry at the double bond. The two flanking methylene groups lie on the same side of the alkene, which fixes their relative orientation at that bond.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 7,652,144 B2
Published
Jan 26, 2010
Filed
Jun 18, 2007
Document BUS 2013/0116256 A1
Published
May 9, 2013
Filed
May 16, 2011
Class
C07D 295/215
Claim 1
Document A
Document B
1.1A2 is CR2, A3 is N, A4 is CR4a, and A6 is C
1.2or A2 is CR2, A3 is N, A4 is O or S, and A6 is C
1.3or A2 is CR2, A3 is C, A4 is O or S and A6 is C
1.4A2 is N, A3 is C, A4 is O or S and A6 is C
1.5or A2 is N, A3 is C, A4 is CR4a, and A6 is N
1.6RA is hydrogen, CH3, halogen, CN, CH2F, CHF2, or CF3
Exemplary alkyl groups include methyl, fluoromethyl, difluoromethyl, trifluoromethyl, cyclopropylmethyl, cyclopentylmethyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, 3-pentyl, heptyl, octyl, nonyl, decyl and dodecyl; preferred are methyl, difluoromethyl and i-propyl.
A · US 7,652,144 B2 · ¶ 50
1.7X is O, or N(Rx2)
R1 represents phenyl; a phenyl-C1-C6 alkyl-, wherein the phenyl is unsubstituted or substituted with 1-4 (e.g., 1-2, 1, 2, 3 or 4) substituents independently selected from the group consisting of: halogen, nitro, hydroxyl, amino, cyano, C1-C6 alkyl, C1-C6 alkoxy, and C1-C6 haloalkyl, wherein the alkyl, alkoxy and haloalkyl may be optionally substituted with hydroxyl, —O—(C1-C4)-alkyl, oxo, amino, —NH—(C1-C4)-alkyl, or —N—[(C1-C6)-alkyl]2, or the alkyl, alkoxy and haloalkyl ar
B · US 2013/0116256 A1 · ¶ 12
1.8wherein Rx2 is hydrogen, C1-C3 alkyl, or unsubstituted cyclopropyl
1.9Y is (CH2)m, —CH═CH—(CH2)n—, —(CH2)p—CH═CH—, or —(CH2)q—CH═CH—(CH2)r—
1.10wherein 0, 1, 2, or 3 CH2 groups are each independently replaced by O, N(Rya), C(Rya)(Ryb), C(O), NC(O)Rya, or S(O)2
1.11m is 2, 3, 4, or 5
1.12n is 1, 2, or 3 p is 1, 2, or 3 q is 1 or 2 r is 1 or 2 wherein the sum of q and r is 2 or 3 Rya, at each occurrence, is independently hydrogen, C2-C6 alkenyl, C2-C6 alkynyl, G1, C1-C6 alkyl, or C1-C6 haloalkyl wherein the C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyl, and C1-C6 haloalkyl are optionally substituted with 1 or 2 substituents independently selected from the group consisting of oxo, —N(Ryd)(Rye), G1, —ORyf, —SRyg, —S(O)2N(Ryd)(Rye), and —S(O)2-G1 Ryb is C2-C6 alkenyl, C2-C6 alkynyl, G1, C1-C6 alkyl, or C1-C6 haloalkyl wherein the C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyl, and C1-C6 haloalkyl are optionally substituted with 1 or 2 substituents independently selected from the group consisting of oxo, —N(Ryd)(Rye), G1, —ORyf, —SRyg, —S(O)2N(Ryd)(Rye), and —S(O)2-G1 or Rya and Ryb, together with the carbon atom to which they are attached, form a C3-C7 monocyclic cycloalkyl, C4-C7 monocyclic cycloalkenyl, or a 4-7 membered monocyclic heterocycle wherein the C3-C7 monocyclic cycloalkyl, C4-C7 monocyclic cycloalkenyl, and the 4-7 membered monocyclic heterocycle are each optionally substituted with 1 —ORm and 0, 1, 2, or 3 independently selected Rs groups Ryd, Rye, Ryf, and Ryg, at each occurrence, are each independently hydrogen, G1, C1-C6 alkyl, or C1-C6 haloalkyl wherein the C1-C6 alkyl and the C1-C6 haloalkyl are optionally substituted with one substituent selected from the group consisting of G1, —ORyh, —SRyh, —SO2Ryh, and —N(Ryi)(Ryk) G1, at each occurrence, is piperazinyl, piperidinyl, pyrrolidinyl, thiomorpholinyl, tetrahydropyranyl, morpholinyl, oxetanyl, 1,3-dioxolanyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxepanyl, or 1,4-dioxepanyl wherein each G1 is optionally substituted with 1 —ORm and 0, 1, 2, or 3 substituents independently selected from the group consisting of G2, —(C1-C6 alkylenyl)-G2, and Rs G2, at each occurrence, is a C3-C7 monocyclic cycloalkyl, C4-C7 monocyclic cycloalkenyl, oxetanyl, morpholinyl, 1,3-dioxolanyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxepanyl, or 1,4-dioxepanyl wherein each G2 is optionally substituted with 1 —ORm and 0, 1, or 2 independently selected Rt groups R2 is independently hydrogen, halogen, CH3, or CN R4a, at each occurrence, is independently hydrogen, halogen, CN, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 alkyl, C1-C4 haloalkyl, GA, C1-C4 alkyl-GA, or C1-C4 alkyl-O-GA wherein each GA is independently C6-C10 aryl, C3-C7 monocyclic cycloalkyl, C4-C7 monocyclic cycloalkenyl, or 4-7 membered heterocycle wherein each GA is optionally substituted with 1, 2, or 3 Ru groups R5 is independently hydrogen, halogen, G3, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl wherein the C1-C6 alkyl, C2-C6 alkenyl, and C2-C6 alkynyl are each optionally substituted with one G3 G3, at each occurrence, is independently C6-C10 aryl, 5-11 membered heteroaryl, C3-C11 cycloalkyl, C4-C11 cycloalkenyl, oxetanyl, 2-oxaspiro[3.3]heptanyl, 1,3-dioxolanyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxepanyl, 2,3-dihydro-1,4-dioxinyl, or 1,4-dioxepanyl wherein each G3 is optionally substituted with 1, 2, or 3 Rv groups A7 is N or CR7 A8 is N or CR8 A15 is N or CR15 R7, R12 and R16 are each independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, —CN, —OR7a, —SR7a, or —N(R7b)(R7c) R8, R13, R14, and R15, are each independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, —CN, —OR8a, —SR8a, —N(R8b)(R8c), or C3-C4 monocyclic cycloalkyl wherein the C3-C4 monocyclic cycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of halogen, C1-C3 alkyl, and C1-C3 haloalkyl or R8 and R13 are each independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, —CN, —OR8a, —SR8a, —N(R8b)(R8c), or C3-C4 monocyclic cycloalkyl wherein the C3-C4 monocyclic cycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of halogen, C1-C3 alkyl, and C1-C3 haloalkyl R14 and R15, together with the carbon atoms to which they are attached, form a monocyclic ring selected from the group consisting of benzene, cyclobutane, cyclopentane, and pyridine wherein the monocyclic ring is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 haloalkyl, —CN, —OR8a, —SR8a, and —N(R8b)(R8c) R9 is —OH, —O—C1-C4 alkyl, —O—CH2—OC(O)(C1-C6 alkyl), —NHOH, or —N(H)S(O)2—(C1-C6 alkyl) R10A and R10B, are each independently hydrogen, C1-C3 alkyl, or C1-C3 haloalkyl or R10A and R10B, together with the carbon atom to which they are attached, form a cyclopropyl wherein the cyclopropyl is optionally substituted with one or two substituents independently selected from the group consisting of halogen and CH3 W is —CH═CH—, C1-C4 alkyl, —O—CHF—, -L1-CH2—, or —CH2-L1- wherein L1 at each occurrence, is independently O, S, S(O), S(O)2, S(O)2N(H), N(H), or N(C1-C3 alkyl) R11 is a C6-C10 aryl or a 5-11 membered heteroaryl wherein each R11 is optionally substituted with 1, 2, or 3 independently selected Rw groups Rw, at each occurrence, is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, C1-C6 haloalkyl, —CN, NO2, —OR11a, —SR11b, —S(O)2R11b, —S(O)2N(R11c)2, —C(O)R11a, —C(O)N(R11c)2, —N(R11c)2, —N(R11c)C(O)R11b, —N(R11c)S(O)2R11b, —N(R11c)C(O)O(R11b), —N(R11c)C(O)N(R11c)2, G4, —(C1-C6 alkylenyl)-OR11a, —(C1-C6 alkylenyl)-OC(O)N(R11c)2, —(C1-C6 alkylenyl)-SR11a, —(C1-C6 alkylenyl)-S(O)2R11b, —(C1-C6 alkylenyl)-S(O)2N(R11c)2, —(C1-C6 alkylenyl)-C(O)R11a, —(C1-C6 alkylenyl)-C(O)N(R11c)2, —(C1-C6 alkylenyl)-N(R11c)2, —(C1-C6 alkylenyl)-N(R11c)C(O)R11b, —(C1-C6 alkylenyl)-N(R11c)S(O)2R11b, —(C1-C6 alkylenyl)-N(R11c)C(O)O(R11b), —(C1-C6 alkylenyl)-N(R11c)C(O)N(R11c)2, —(C1-C6 alkylenyl)-CN, or —(C1-C6 alkylenyl)-G4 R11a and R11c, at each occurrence, are each independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 haloalkyl, G4, —(C2-C6 alkylenyl)-OR11d, —(C2-C6 alkylenyl)-N(R11e)2, or —(C2-C6 alkylenyl)-G4 R11b, at each occurrence, is independently C1-C6 alkyl, C2-C6 alkenyl, C1-C6 haloalkyl, G4, —(C2-C6 alkylenyl)-OR11d, —(C2-C6 alkylenyl)-N(R11e)2, or —(C2-C6 alkylenyl)-G4 G4, at each occurrence, is independently phenyl, monocyclic heteroaryl, C3-C11 cycloalkyl, C4-C11 cycloalkenyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 2,6-dioxa-9-azaspiro[4.5]decanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 3-oxa-8-azabicyclo[3.2.1]octanyl, piperidinyl, piperazinyl, azetidinyl, morpholinyl, dihydropyranyl, tetrahydropyridinyl, dihydropyrrolyl, pyrrolidinyl, 2,3-dihydrodioxinyl, 1,3-dioxolanyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxepanyl, or 1,4-dioxepanyl wherein each G4 is optionally substituted with 1 —ORm and 0, 1, 2, or 3 substituents independently selected from the group consisting of G5, Ry, —(C1-C6 alkylenyl)-G5, —(C1-C6 alkylenyl)-L2-(C1-C6 alkylenyl)-G5, and -L2-(C1-C6 alkylenyl)s-G5 L2 is O, C(O), N(H), N(C1-C6 alkyl), NHC(O), C(O)O, S, S(O), or S(O)2 s is 0 or 1 G5, at each occurrence, is independently phenyl, monocyclic heteroaryl, C3-C7 monocyclic cycloalkyl, C4-C7 monocyclic cycloalkenyl, piperazine, 1,3-dioxolanyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxepanyl, or 1,4-dioxepanyl wherein each G5 is optionally substituted with 1 independently selected —ORm or 0, 1, 2, or 3 Rz groups Rs, Rt, Ru, Rv, Ry, and Rz, at each occurrence, are each independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, C1-C6 haloalkyl, —CN, oxo, NO2, P(O)(Rk)2, —OC(O)Rk, —OC(O)N(Rj)2, —SRj, —S(O)2Rk, —S(O)2N(Rj)2, —C(O)Rj, —C(O)N(Rj)2, —N(Rj)2, —N(Rj)C(O)Rk, —N(Rj)S(O)2Rk, —N(Rj)C(O)O(Rk), —N(Rj)C(O)N(Rj)2, —(C1-C6 alkylenyl)-ORj, (C1-C6 alkylenyl)-OC(O)N(Rj)2, —(C1-C6 alkylenyl)-SRj, —(C1-C6 alkylenyl)-S(O)2Rk, —(C1-C6 alkylenyl)-S(O)2N(Rj)2, —(C1-C6 alkylenyl)-C(O)Rj, —(C1-C6 alkylenyl)-C(O)N(Rj)2, —(C1-C6 alkylenyl)-N(Rj)2, —(C1-C6 alkylenyl)-N(Rj)C(O)Rk, —(C1-C6 alkylenyl)-N(Rj)S(O)2Rk, —(C1-C6 alkylenyl)-N(Rj)C(O)O(Rj), —(C1-C6 alkylenyl)-N(Rj)C(O)N(Rj)2, or —(C1-C6 alkylenyl)-CN Rm is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, —(C2-C6 alkylenyl)-ORj, or -(C2-C6 alkylenyl)-N(Rj)2 Ryh, Ryi, Ryk, R7a, R7b, R7c, R8a, R8b, R8c, R11d, R11e, and Rj, at each occurrence, are each independently hydrogen, C1-C6 alkyl, or C1-C6 haloalkyl Rk, at each occurrence, is independently C1-C6 alkyl or C1-C6 haloalkyl wherein at least one of G1, G2, G3, G4, and G5 is 2,2-dimethyl-1,3-dioxolanyl, 2,3-dihydro-1,4-dioxinyl, 1,3-dioxolanyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxepanyl, or 1,4-dioxepanyl.
R3 is optionally substituted aryl or heteroaryl, wherein the substituted aryl or substituted heteroaryl group is substituted by one or more substituents which may be the same or different and are selected from alkyl, aryl, aralkyl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkyloxy, carboxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxycarboxyl, aryloxycarbonyl, aralkyloxycarbonyl, acylamino, aroylamino, alkylsulfonyl, arylsulfonyl, alkylsulfinyl, arylsulfinyl, alkylthio,
A · US 7,652,144 B2 · ¶ 41
R1 represents phenyl, a phenyl-C1-C6 alkyl-, wherein the phenyl is unsubstituted or substituted with 1-4 (e.g., 1-2, 1, 2, 3 or 4) substituents independently selected from the group consisting of: halogen, nitro, hydroxyl, amino, cyano, a C1-C6 alkyl, a C1-C6 alkoxy, and a C1-C6 haloalkyl, wherein the alkyl, alkoxy and haloalkyl may be optionally substituted with hydroxyl, a —O—(C1-C4)-alkyl, oxo, amino, a —NH—(C1-C4)-alkyl, or a —N—[(C1-C6)-alkyl]2, or the alkyl, alkoxy and
B · US 2013/0116256 A1 · claim 2

An empty cell means only that no passage was reproduced there.

Statements in these documents
Disease states associated with abnormally high physiological levels of cytokines such as TNF are treatable according to the invention.
A · US 7,652,144 B2 · ¶ 3
Disease states associated with pathological conditions that are modulated by inhibiting enzymes, which are associated with secondary cellular messengers, such as cyclic AMP phosphodiesterase, are also treatable according to the invention Cyclic AMP phosphodiesterase is an important enzyme which regulates cyclic AMP levels and in turn thereby regulates other important biological reactions.
A · US 7,652,144 B2 · ¶ 7
However, there are few kinds and numbers of drugs so far that can be clinically used for combating apoptosis and protecting cells, and their selectivity and targeting property are not satisfied, and therefore it is of great significance to continuously develop new, safe and effective drugs for combating apoptosis and protecting cells, and especially drugs with a novel mechanism of action.
B · US 2013/0116256 A1 · ¶ 7
In order to develop new, safe and effective drugs for combating apoptosis and protecting cells, after conducting extensive experimental researches for a long term the inventors have found a group of hexenone compounds that have effects of combating apoptosis and protecting myocardial cells, and can be used for prophylaxis or treatment of diseases or disorders associated with cardiomyocyte apoptosis.
B · US 2013/0116256 A1 · ¶ 8
Cite aspatent.fyi, US 2026/0356848 A1, claim 1, first published 2026-11-20T08:11:50-05:00, https://patent.fyi/US20260356848/, SHA-256 ada04ad65f120d6a2b33033efed69f96dbaf1a597d609338aa948b2f913de481
First published
Permanent addresshttps://patent.fyi/US20260356848/
Content fingerprint (SHA-256)ada04ad65f120d6a2b33033efed69f96dbaf1a597d609338aa948b2f913de481
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi